NCT01334658

Brief Summary

This is a study aimed at evaluating the effectiveness and impact of two intraocular irrigating solution (BSS ® versus glucose-bicarbonate-Ringer Lactate - GBRL) on the health of the cornea after cataract surgery by phacoemulsification.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2010

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2010

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2011

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 8, 2011

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 13, 2011

Completed
Last Updated

April 13, 2011

Status Verified

April 1, 2011

Enrollment Period

6 months

First QC Date

April 8, 2011

Last Update Submit

April 12, 2011

Conditions

Keywords

Corneal endotheliumCataract surgeryIrrigation solutions intraocularPhacoemulsification

Outcome Measures

Primary Outcomes (6)

  • Increase in central corneal thickness (CCT)

    Two days after surgery.

  • Increase in central corneal thickness (CCT)

    Thirty days after surgery.

  • Increase in central corneal thickness (CCT)

    Ninety days after surgery.

  • Decrease in the percentage of endothelial cell density (ECD)

    Two days after surgery.

  • Decrease in the percentage of endothelial cell density (ECD)

    Thirty days after surgery.

  • Decrease in the percentage of endothelial cell density (ECD)

    Ninety days after surgery.

Study Arms (2)

Balanced Salt Solution (BSS®)

ACTIVE COMPARATOR

Subjects who received Balanced Salt Solution.

Procedure: Phacoemulsification cataract surgeryDrug: Balanced Salt Solution (BSS®)

Glucose-bicarbonate-Ringer Lactate (GBRL)

ACTIVE COMPARATOR

Subjects who received glucose-bicarbonate-Ringer Lactate.

Procedure: Phacoemulsification cataract surgeryDrug: Glucose-bicarbonate-Ringer Lactate (GBRL)

Interventions

A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery. All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).

Balanced Salt Solution (BSS®)Glucose-bicarbonate-Ringer Lactate (GBRL)

A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery. All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).

Glucose-bicarbonate-Ringer Lactate (GBRL)

A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery. All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).

Balanced Salt Solution (BSS®)

Eligibility Criteria

Age50 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Uncomplicated senile cataract
  • Visual acuity (VA) between 20/40 and 20/400
  • Healthy corneas

You may not qualify if:

  • Mental incapacity
  • Patients with coexisting diseases of the cornea
  • Presence of corneal opacity
  • Uncontrolled glaucoma
  • Uncontrolled diabetes mellitus
  • Uveitis
  • Cells or flare in the anterior chamber
  • Prior intraocular surgery
  • Patients using topical steroids or systemic
  • Traumatic cataract, hereditary or toxic

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Cataract

Condition Hierarchy (Ancestors)

Lens DiseasesEye Diseases

Study Officials

  • Hermelino L Oliveira Neto

    CLIHON

    STUDY DIRECTOR
  • Israel C Marques Neto

    State University of Feira de Santana (UEFS)

    PRINCIPAL INVESTIGATOR
  • Brunno B Barros

    State University of Feira de Santana (UEFS)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 8, 2011

First Posted

April 13, 2011

Study Start

August 1, 2010

Primary Completion

February 1, 2011

Study Completion

February 1, 2011

Last Updated

April 13, 2011

Record last verified: 2011-04